Urticaria News and Research

RSS
Urticaria are itchy, raised red areas on the skin. Urticaria are caused by a reaction to certain foods, drugs, infections, or emotional stress. Also called hives.
AMAG fourth quarter total revenues increase to $17.2 million

AMAG fourth quarter total revenues increase to $17.2 million

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

State court jury rules in favor of Merck in FOSAMAX trial

State court jury rules in favor of Merck in FOSAMAX trial

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

Dermatologists offer preventative tips to minimize pesky skin problems caused by plants

Dermatologists offer preventative tips to minimize pesky skin problems caused by plants

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Shionogi brings KAPVAY ADHD drug to the U.S market

Shionogi brings KAPVAY ADHD drug to the U.S market

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

ISTA commences bepotastine besilate nasal spray Phase 2 study in seasonal allergic rhinitis

ISTA commences bepotastine besilate nasal spray Phase 2 study in seasonal allergic rhinitis

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Merck wins third FOSAMAX bellwether trial

Merck wins third FOSAMAX bellwether trial

FDA approves Sun Pharma's generic Clarinex ANDA

FDA approves Sun Pharma's generic Clarinex ANDA

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Dyax to present data of KALBITOR inhibitor for Angioedema at ACAAI Meeting

Dyax to present data of KALBITOR inhibitor for Angioedema at ACAAI Meeting

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis